Loading…
Anika Therapeutics, Inc. is projected to rise to $18.50 by 2027, a +19% move from its current price of $15.60. ANIK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $15.29 | $15.60 | $15.90 | -0.02% |
| Jul 13 | $15.17 | $15.59 | $16.03 | -0.05% |
| Jul 14 | $15.07 | $15.59 | $16.13 | -0.07% |
| Jul 15 | $14.99 | $15.59 | $16.21 | -0.09% |
| Jul 16 | $14.91 | $15.58 | $16.28 | -0.12% |
| Jul 17 | $14.85 | $15.58 | $16.34 | -0.14% |
| Jul 18 | $14.79 | $15.57 | $16.40 | -0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.79 | $15.57 | $16.40 | -0.16% |
| Week 2 | $14.45 | $15.55 | $16.73 | -0.33% |
| Week 3 | $14.19 | $15.52 | $16.98 | -0.49% |
| Week 4 | $13.97 | $15.50 | $17.19 | -0.66% |
| Week 5 | $13.78 | $15.47 | $17.37 | -0.82% |
| Week 6 | $13.61 | $15.45 | $17.54 | -0.98% |
| Week 7 | $13.45 | $15.42 | $17.69 | -1.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Anika Therapeutics, Inc. is a joint preservation company that focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions.
It also markets Cingal, a non-opioid, single-injection OA pain management product, along with regenerative solutions like an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments. Anika also develops Hyalofast, a resorbable scaffold used for single stage cartilage regeneration, and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. The company provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products include Hyvisc, a high molecular weight injectable HA veterinary product for joint dysfunction in horses, Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries, ophthalmic products, and Anikavisc and Nuvisc high molecular weight HA products.
The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Anika Therapeutics, Inc. is currently trading at $15.36 per share, with a market capitalization of $204.37M. The company holds a rank of 3715 by market cap. The price outlook reflected in the forecast shows a bullish long-term trajectory, with the average forecast price rising from $15.36 in 2026 to $222.03 in 2050, signaling meaningful upside over the period.
The sentiment flags a transition from neutral in 2026 to bullish in later years, underscoring an expected growth path alongside the expanding multi-year forecast.
A major floor 20.6% below — a decisive break under it would weaken the trend.
The nearest floor, 9.0% below — buyers have tended to step in here.
The nearest ceiling, 4.7% above — a clean break opens room to run.
A major ceiling 12.3% above — clearing it would confirm fresh momentum.
Key ANIK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANIK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.99 | Sell | $15.80 | Sell |
| MA 10 | $15.52 | Buy | $15.56 | Buy |
| MA 20 | $15.02 | Buy | $15.25 | Buy |
| MA 50 | $14.79 | Buy | $14.85 | Buy |
| MA 100 | $14.47 | Buy | $14.10 | Buy |
| MA 200 | $12.03 | Buy | $13.29 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.01 | Neutral |
| Stoch RSI (14) | 52.96 | Neutral |
| CCI (20) | 71.52 | Neutral |
| Williams %R (14) | -34.58 | Info |
| MACD (12,26,9) | 0.13 | Buy |
| ROC (12) | 6.92 | Buy |
| Bollinger %B (20,2) | 0.73 | Neutral |
| Stochastic %K (14) | 65.42 | Neutral |
| TRIX (15) | 0.18 | Buy |
| Awesome (5,34) | 1.10 | Buy |
| Ultimate (7,14,28) | 64.76 | Neutral |
| Momentum (10) | 0.98 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 16.26 | Sell |
| ADX (14) | 13.82 | Neutral |
| ATR (14) | 0.30 | Info |
The 30-day technical picture is bullish, with sentiment labeled BULLISH. The RSI14 is 60, and the stock is trading relative to moving averages with SMA50 at $14.74 and SMA200 at $11.85. Support is identified at $14.20 and resistance at $15.36, outlining a near-term constructive setup.
The 30-day range runs from $13.63 to $17.31, and annualized volatility stands at 30%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.13 | $15.60 | $19.58 | 0% | Neutral | |
| $15.11 | $18.50 | $23.70 | +19% | Neutral | |
| $16.99 | $21.21 | $27.93 | +36% | Bullish | |
| $18.98 | $24.07 | $32.40 | +54% | Bullish | |
| $23.96 | $30.81 | $42.24 | +97% | Bullish | |
| $26.39 | $34.36 | $47.88 | +120% | Bullish | |
| $26.52 | $34.95 | $49.41 | +124% | Bullish | |
| $29.34 | $39.08 | $55.99 | +151% | Bullish | |
| $30.29 | $40.77 | $59.14 | +161% | Bullish | |
| $33.04 | $44.91 | $65.89 | +188% | Bullish | |
| $49.18 | $69.85 | $107.54 | +348% | Bullish | |
| $99.76 | $152.52 | $252.17 | +878% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.13 | $15.60 | $18.37 | +0.00% |
| August 2026 | $12.91 | $15.12 | $18.11 | -3.05% |
| September 2026 | $12.97 | $15.27 | $18.43 | +0.96% |
| October 2026 | $13.33 | $15.76 | $19.16 | +3.25% |
| November 2026 | $13.33 | $15.82 | $19.34 | +0.37% |
| December 2026 | $13.39 | $15.94 | $19.58 | +0.72% |
Click any year to see its month-by-month ANIK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ANIK to range from $9.13 to $19.58 through 2026. The $15.60 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ANIK price prediction for 2027 points to an average of $18.50 (low $15.11, high $23.70) — a potential gain of +19% on today's $15.60. A consolidation phase looks the most probable path here.
In 2028, ANIK is projected to trade between $16.99 and $27.93, averaging $21.21 — a potential gain of +36% from today's $15.60. That is up +15% on the projected 2027 average. Momentum favours further upside here.
Anika Therapeutics, Inc.'s 2029 outlook centres on $24.07, within a $18.98 to $32.40 range. That is up +14% on the projected 2028 average. That marks a +54% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, ANIK could reach as high as $42.24, with a base case around $30.81 and support toward $23.96 — roughly +97% from $15.60. Momentum favours further upside here.
Expect ANIK to range from $26.39 to $47.88 through 2031. The $34.36 average target implies a +120% move from current prices. That is up +12% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ANIK price prediction for 2032 points to an average of $34.95 (low $26.52, high $49.41) — a potential gain of +124% on today's $15.60. Momentum favours further upside here.
In 2033, ANIK is projected to trade between $29.34 and $55.99, averaging $39.08 — a potential gain of +151% from today's $15.60. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Anika Therapeutics, Inc.'s 2034 outlook centres on $40.77, within a $30.29 to $59.14 range. That is up +4% on the projected 2033 average. That marks a +161% change versus current levels. Momentum favours further upside here.
By 2035, ANIK could reach as high as $65.89, with a base case around $44.91 and support toward $33.04 — roughly +188% from $15.60. Buyers look set to stay in control over this stretch.
Expect ANIK to range from $49.18 to $107.54 through 2040. The $69.85 average target implies a +348% move from current prices. That is up +56% on the projected 2035 average. Momentum favours further upside here.
The ANIK price prediction for 2050 points to an average of $152.52 (low $99.76, high $252.17) — a potential gain of +878% on today's $15.60. Buyers look set to stay in control over this stretch.
Investing $1,000 in ANIK today (≈ 64.102564 ANIK) could be worth
$9,776.65
+$8,776.65 (+878%) by 2050 · US Dollar
Based on the average projected ANIK price of $152.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANIKwould be worth at today's price.
$1,000 invested in ANIK on Jul 10, 2025 (≈ 84.889645 ANIK) would be worth
$1,324.28
+$324.28 (+32.4%) today · 1.32× · US Dollar
Based on a ANIK entry price of $11.78 vs. today's $15.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.36 | $1,015.63 | +1.6% |
| 1 month ago | $14.95 | $1,043.48 | +4.3% |
| 3 months ago | $14.76 | $1,056.91 | +5.7% |
| 6 months ago | $9.41 | $1,657.81 | +65.8% |
| 1 year ago | $11.78 | $1,324.28 | +32.4% |
| All time (5.0y) ago | $43.01 | $362.71 | -63.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANIK forecast.
Our base-case forecast reaches $31.00 around 2031.
Implied market cap at $31.00: $412.47M
Looking across the multi-year forecast, the asset shows a clear upward trajectory. For 2030, the average forecast price is $35.72 with a min of $27.89 and a max of $48.71, and the ROI is 132.5, with bullish sentiment evident in 2030 and beyond. The forecast continues to trend higher through 2031–2035, with average prices of $40.17, $41.90, $47.98, $50.80, and $57.83 respectively, and ROIs of 161.5, 172.8, 212.3, 230.7, and 276.5.
By 2040, the average is $92.93 with an ROI of 505, maintaining bullish sentiment. In 2050, the average reaches $222.03 with an ROI of 1345.5, sustaining a bullish outlook through the end of the forecast horizon. These are estimates and not guarantees.
The data reflect a growth path with rising averages and expanding upside, tempered by typical investment risks.
Tap a question to reveal the answer.
2030 forecast: average price $35.72, min $27.89, max $48.71; ROI 132.5. These are estimates, not guarantees.
Forecasts show bullish sentiment from 2027 onward, with average prices climbing to $222.03 by 2050 and ROI up to 1345.5. Current price is $15.36 and the 30-day range is $13.63-$17.31; these are estimates, not guarantees.
Yes. The 2034 forecast shows an average price of $50.80 and a maximum of $73.15.
The 30-day price range is $13.63 to $17.31.
Current price is $15.36; market capitalization is $204.37M.
Anika Therapeutics, Inc. Community Discussion
0Share your Anika Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.